RNA
Avidity Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.19
−2.81%Jun 23, 2026, 19:51 UTC
Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.
Source:Jun 11, 2026, 21:41 UTC
Novartis acquired Avidity as part of a $12 billion takeover.
Source: